Continuing Medical Education
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
Credit Designation Statement
AACR has designated this live activity for a maximum of 13.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
Claiming CME Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by Wednesday, November 17, 2021. Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive ABIM MOC, participants must request MOC in the CME Request for Credit Survey and complete all questions. Once these steps are completed, AACR will submit your completion information via the ACCME’s Program and Activity Reporting System for the purpose of granting MOC points.
Statement of Educational Need, Target Audience, and Learning Objectives
The field of immunotherapy is one of the most promising in cancer research. Utilizing the body’s immune system to fight cancer is often safer and better tolerated than traditional cancer treatments such as chemotherapy and radiation. Study and understanding of the immune system’s response to cancer has increased exponentially over the past several years, and this has given rise to many breakthrough cancer treatments.
Types of immunotherapies include radio- or chemolabeled monoclonal antibodies (including checkpoint inhibitors); bispecific monoclonal antibodies; checkpoint immunomodulators such as PD-1, PD-L1, and CTLA-4 inhibitors, which have been approved for treatment of many cancers; adoptive cell transfer (including CAR T cell therapy); therapeutic vaccines for treatment and prevention; cytokines such as interleukins and interferons; and oncolytic viruses.
This conference will feature some of the world’s premier oncologists who will present their latest research on current immunotherapies. It will also help bridge the gap between the advances that are underway in the lab and their application to clinical practice. Current promising research includes engineering of immune cells (macrophages, NK cells) to better target a wider range of malignancies and minimize immune-related adverse events (IRAEs); single-cell analysis to identify distinct populations of cells within the tumor microenvironment that may then be targeted for prevention and treatment; novel therapeutic methods to restore
CAR T cells from exhaustion; finding metabolic targets as therapeutic avenues for immunotherapy; targeting of immunosuppressive cells to overcome resistance; and creating libraries or atlases of immune cell states in order to further facilitate mechanistic and translational studies. This year there will also be a session on how the novel coronavirus affects the immune system of cancer patients, which is very applicable for clinicians today and going forward. The end goal is a deeper understanding of the immune response to cancer in order to design better treatments, overcome resistance, and prevent cancer altogether.
Only through a thorough understanding of the basic immunological science behind these new technologies and collaboration between basic scientists and oncologists can new treatments be developed. For physicians to best aid patients, they must have a solid and current understanding of the complexities of basic immunotherapy and new advances taking place in the lab that can eventually be applied to the clinic. Physicians will leave this conference with knowledge of novel advancements in immunotherapy in the lab and the potential thereof for therapeutic applications.
After participating in this CME activity, physicians should be able to:
- Identify and integrate novel approaches to immune engineering.
- Evaluate non-T-cell therapies to minimize IRAEs and potentially to treat solid tumors.
- Assess immune response to COVID-19 in cancer patients.
- Integrate novel combination and targeted therapies for personalizing cancer immune response and combatting resistance.
- Identify metabolic targets for immunotherapy.
- Integrate single-cell analysis and immune cell atlases to enhance immune activity, personalize therapy, and identify novel targets.
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available on the website of this conference.
Acknowledgment of Financial or Other Support
This activity is supported by Professional Educational Grants which will be disclosed at the activity.
Questions about CME?
Please contact the Office of CME at (215) 440-9300 or [email protected].